Conatus Pharmaceuticals conatuspharma.com

Conatus Pharmaceuticals, a privately-held biotechnology company, is engaged in the development of human therapeutics to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease and acute exacerbations of chronic liver disease. Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis.

Conatus Pharmaceuticals, a privately-held biotechnology company, is engaged in the development of human therapeutics to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease ...Show all

See All Exits Recent Exits

Phone: 858-376-2600

Fax:

16745 West Bernardo Drive
Suite 200
San Diego, 92127
California, United States

Conatus Pharmaceuticals - Investments & Acquisitions

Show Real Data
See all Recent Investments
Date Company Round Amount Co-investors
2010-07-30Idun PharmaceuticalsAcquired - II
See all 1 investments